Identifying Long-Term Survival Candidates among Patients with Isolated Locoregionally Recurrent Breast Cancer: Implications of the Use of Systemic Chemotherapy
- Author:
Byoung Hyuck KIM
1
;
Kyung Hwan SHIN
;
Eui Kyu CHIE
;
Jin Ho KIM
;
Kyubo KIM
;
Ki-Tae HWANG
;
Jongjin KIM
;
In Sil CHOI
;
Jin Hyun PARK
;
Suzy KIM
Author Information
- Publication Type:Original Article
- From:Journal of Breast Cancer 2020;23(3):279-290
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:We aimed to investigate the clinicopathologic factors associated with distant metastasis (DM) and post-recurrence overall survival (OS) after salvage treatments for isolated locoregional recurrence (ILRR) of breast cancer and identify long-term surviving patients for providing a more personalized therapy.
Methods:We analyzed 125 patients who underwent salvage local treatments for ILRR after initial curative breast surgery.
Results:Fifty-two (41.6%) patients experienced secondary recurrence or disease progression, of which 20 (38.5%) experienced a secondary locoregional recurrence and 40 (76.9%) experienced DM as the first site of failure. In multivariate analysis of distant metastasis free survival (DMFS) and post-recurrence OS, the initial pN2-3 stage, a disease-free interval of < 36 months, and non-curative resection for recurrent disease were independently poor prognosticators. The score for patients stratified according to the number of risk factors increased from 0 to 3; the corresponding 5-year DMFS rates were 91.4%, 53.0%, 35.9%, and 0% and the 5-year OS rates were 97.3%, 70.4%, 32.7%, and 25.0%, respectively (p < 0.001).Systemic chemotherapy reduced DM in patients with a score of 2–3, but it did not in those with a score of 0-1.
Conclusion:Our collective stratification can help with prognosis prediction for ILRR of breast cancer. Depending on the DM risk of patients, the potential combination of systemic therapy should be discussed further.
